Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC) - Trial NCT06311045
Access comprehensive clinical trial information for NCT06311045 through Pure Global AI's free database. This phase not specified trial is sponsored by NYU Langone Health and is currently Not yet recruiting. The study focuses on Obstructive Sleep Apnea. Target enrollment is 206 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
NYU Langone Health
Timeline & Enrollment
N/A
Apr 01, 2024
Dec 01, 2028
Primary Outcome
Percent Change in Overnight Levels of Glutathione (GSH),Mean Change in Pre- to Post-Sleep GSH Levels,Mean Change in Pre- to Post-Sleep GSH Levels
Summary
This is a randomized controlled trial (RCT) of 4 weeks of study supplement N-acetylcysteine
 (NAC) versus placebo in persons with significant obstructive sleep apnea (OSA) who are
 receiving positive airway pressure therapy (PAP), the standard of care therapy. The purpose
 of the study is to determine if NAC is associated with sex-specific changes in overnight
 oxidative stress, inflammation, as well as endothelial dysfunction in persons with OSA.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06311045
Non-Device Trial